Abstract | BACKGROUND: Morbidly placenta accreta as a cause of postpartum morbidity is increasing in incidence. One conservative option is use of methotrexate as an adjuvant therapy for the management of placenta accreta. There is concern that use of methotrexate in a lactating mother could potentially expose her neonate to harmful effects of this medication. CASE REPORT: Here we report a 29-year-old woman subjected to methotrexate treatment for placenta accreta. Her child was delivered at 32 weeks weighing 3 lbs. On postpartum day 5, this patient was diagnosed with placenta accreta and treated with intramuscular methotrexate for 3 consecutive days. She received 92 mg methotrexate intramuscularly daily, and was advised not to breastfeed. She collected milk samples on day 2, the 0 hour before the second dose and at 1, 2, 4, 8, 12, and 24 hours after taking the dose. A high-performance liquid chromatography mass spectrometry method was developed to measure methotrexate and its metabolite 7-hydroxymethotrexate levels in milk samples. DISCUSSION: CONCLUSION: This case report found the relative infant dose of methotrexate to be 0.11%. Methotrexate does transfer into breast milk, although the levels detected were very low. However, caution should still be used in counseling mothers regarding breastfeeding with this toxic drug.
|
Authors | Teresa Baker, Palika Datta, Kathleen Rewers-Felkins, Thomas W Hale |
Journal | Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine
(Breastfeed Med)
2018 Jul/Aug
Vol. 13
Issue 6
Pg. 450-452
ISSN: 1556-8342 [Electronic] United States |
PMID | 29985651
(Publication Type: Case Reports, Journal Article)
|
Chemical References |
- 7-hydroxymethotrexate
- Methotrexate
|
Topics |
- Adult
- Breast Feeding
- Female
- Humans
- Injections, Intramuscular
- Methotrexate
(administration & dosage, analogs & derivatives, analysis)
- Milk, Human
(chemistry)
- Placenta Accreta
(drug therapy)
- Postpartum Period
- Pregnancy
- Time Factors
|